

Wai Tong Ng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/811672/publications.pdf>

Version: 2024-02-01

151
papers

8,077
citations

61857

43
h-index

51492

86
g-index

155
all docs

155
docs citations

155
times ranked

6483
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology</i> , The, 2015, 16, 645-655.	5.1	593
2	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , 2015, 33, 3356-3364.	0.8	579
3	Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2014, 110, 377-384.	0.3	300
4	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1188-1198.	3.0	298
5	Current Management of Nasopharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 233-244.	1.0	274
6	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 498-505.	0.8	263
7	Proposal for the 8th edition of the <sc>AJCC</sc>/<sc>UICC</sc> staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 546-558.	2.0	254
8	Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 420-428.	0.4	236
9	<sc>COVID</sc>-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , 2020, 42, 1259-1267.	0.9	218
10	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
11	Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. <i>European Journal of Cancer</i> , 2011, 47, 656-666.	1.3	196
12	The battle against nasopharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2012, 104, 272-278.	0.3	191
13	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , 2018, 77, 16-21.	0.8	189
14	Management of locally recurrent nasopharyngeal carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 79, 101890.	3.4	186
15	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 1449-1458.	1.2	179
16	Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 1328-1338.	2.0	152
17	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3091-3100.	0.8	147
18	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11283-11288.	3.3	144

#	ARTICLE	IF	CITATIONS
19	Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 981-990.	0.4	126
20	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 3307-3315.	2.0	125
21	The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. <i>Oral Oncology</i> , 2012, 48, 1007-1013.	0.8	109
22	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 98, 15-22.	0.3	102
23	Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1335-1342.	0.4	98
24	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.4	96
25	Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinoma—Patient- and Treatment-Related Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1121-1128.	0.4	95
26	Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2008, 87, 204-210.	0.3	90
27	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. <i>Oral Oncology</i> , 2016, 53, 10-16.	0.8	86
28	N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: Pattern of nodal involvement by radiological levels. <i>Radiotherapy and Oncology</i> , 2007, 82, 70-75.	0.3	84
29	The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. <i>Oral Oncology</i> , 2014, 50, 506-512.	0.8	83
30	Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1079-1090.	1.3	76
31	Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. <i>International Journal of Cancer</i> , 2015, 136, E127-35.	2.3	72
32	Whole-exome sequencing identifies <i>MST1R</i> as a genetic susceptibility gene in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3317-3322.	3.3	71
33	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017, 123, 4147-4157.	2.0	70
34	Screening for family members of patients with nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2005, 113, 998-1001.	2.3	67
35	Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1331-1338.	0.4	66
36	Therapeutic targeting of CBP/ β -catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. <i>Scientific Reports</i> , 2015, 5, 9979.	1.6	59

#	ARTICLE	IF	CITATIONS
37	Reirradiation with intensityâ€modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 533-540.	0.9	57
38	A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. <i>Molecular Cancer</i> , 2013, 12, 128.	7.9	54
39	Treatment of Stage IV(Aâ€B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1004-1010.	0.4	51
40	Nasopharyngeal carcinoma: Salvage of local recurrence. <i>Oral Oncology</i> , 2012, 48, 768-774.	0.8	50
41	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2021, 153, 109-122.	1.3	48
42	Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres. <i>Cancer Letters</i> , 2013, 335, 81-92.	3.2	47
43	Staging of nasopharyngeal carcinoma â€ The past, the present and the future. <i>Oral Oncology</i> , 2014, 50, 549-554.	0.8	47
44	Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. <i>Oral Oncology</i> , 2017, 67, 52-60.	0.8	46
45	Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. <i>Head and Neck</i> , 2006, 28, 880-887.	0.9	45
46	Clinical utility of plasma Epsteinâ€Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	2.0	43
47	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
48	Chemotherapy for Nasopharyngeal Carcinoma â€ Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1107-1122.	0.9	39
49	Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: The importance of co-morbidity assessment. <i>Oral Oncology</i> , 2012, 48, 162-167.	0.8	38
50	Quality of life in head and neck cancer survivors at 1Âyear after treatment: the mediating role of unmet supportive care needs. <i>Supportive Care in Cancer</i> , 2014, 22, 2917-2926.	1.0	38
51	The prognostic value of histological typing in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 429-433.	0.8	37
52	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	37
53	NPCâ€0501 trial on the value of changing chemoradiotherapy sequence, replacing 5â€fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2020, 126, 3674-3688.	2.0	37
54	Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. <i>Familial Cancer</i> , 2010, 9, 221-228.	0.9	36

#	ARTICLE	IF	CITATIONS
55	Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. <i>Head and Neck</i> , 2012, 34, 1225-1230.	0.9	36
56	Parapharyngeal Extension of Nasopharyngeal Carcinoma: Still a Significant Factor in Era of Modern Radiotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1082-1089.	0.4	34
57	Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. <i>Familial Cancer</i> , 2009, 8, 103-108.	0.9	34
58	Treatment of primary liver cancer using highly-conformal radiotherapy with kv-image guidance and respiratory control. <i>Radiotherapy and Oncology</i> , 2012, 102, 56-61.	0.3	34
59	Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. <i>Oral Oncology</i> , 2013, 49, 49-54.	0.8	34
60	Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 630-638.	0.4	34
61	Metastasis-suppressing <i>NID2</i> , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 78859-78871.	0.8	33
62	Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?. <i>American Journal of Infection Control</i> , 2016, 44, 394-399.	1.1	31
63	A Mixed-Methods Study of Unmet Supportive Care Needs Among Head and Neck Cancer Survivors. <i>Cancer Nursing</i> , 2019, 42, 67-78.	0.7	31
64	Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?. <i>Oral Oncology</i> , 2014, 50, 1188-1195.	0.8	30
65	NF- κ B p53 Subunit Is Modulated by Latent Transforming Growth Factor- β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. <i>PLoS ONE</i> , 2015, 10, e0127239.	1.1	29
66	Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. <i>Frontiers in Oncology</i> , 2017, 7, 221.	1.3	28
67	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT—A study by the HKNPCSC. <i>Head and Neck</i> , 2019, 41, 3661-3669.	0.9	28
68	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. <i>Cancer Treatment Reviews</i> , 2020, 85, 101995.	3.4	28
69	Multigene pathway-based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of <i>TERT</i> and <i>CLPTM1L</i> and DNA double-strand breaks repair. <i>International Journal of Cancer</i> , 2014, 135, 1634-1645.	2.3	26
70	Automatic segmentation for adaptive planning in nasopharyngeal carcinoma IMRT: Time, geometrical, and dosimetric analysis. <i>Medical Dosimetry</i> , 2020, 45, 60-65.	0.4	26
71	Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 703995.	1.3	25
72	Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. <i>BMC Cancer</i> , 2011, 11, 288.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1078-1086.	0.4	23
74	Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. <i>Frontiers in Oncology</i> , 2020, 10, 593164.	1.3	23
75	A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 441-444.	0.8	21
76	Trends and Patterns of Breast Conservation Treatment in Hong Kong: 1994–2007. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 98-103.	0.4	20
77	Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1414-1420.	0.4	20
78	Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. <i>Phytomedicine</i> , 2019, 63, 153058.	2.3	19
79	Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. <i>Gastric Cancer</i> , 2011, 14, 63-71.	2.7	18
80	If concurrent—adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction—concurrent achieve better outcome?. <i>Journal of Radiation Oncology</i> , 2012, 1, 107-115.	0.7	18
81	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 59-68.	0.9	18
82	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. <i>Communications Biology</i> , 2020, 3, 759.	2.0	17
83	Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. <i>Diagnostics</i> , 2021, 11, 1467.	1.3	17
84	Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. <i>Current Treatment Options in Oncology</i> , 2015, 16, 44.	1.3	16
85	Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSC. <i>Oral Oncology</i> , 2020, 111, 105012.	0.8	16
86	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 114-125.	2.9	14
87	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6523-6523.	0.8	14
88	Is Selective Neck Irradiation Safe for Node-Negative Nasopharyngeal Carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 902-903.	0.4	13
89	MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2017, 7, 12012.	1.6	13
90	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6002-6002.	0.8	13

#	ARTICLE	IF	CITATIONS
91	An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. <i>Familial Cancer</i> , 2011, 10, 133-139.	0.9	12
92	IKBB tumor suppressive role in nasopharyngeal carcinoma via NF- κ B-mediated signalling. <i>International Journal of Cancer</i> , 2016, 138, 160-170.	2.3	12
93	Dose volume effects of re-irradiation for locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 180-187.	0.9	11
94	Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). <i>Magnetic Resonance Imaging</i> , 2021, 83, 50-56.	1.0	11
95	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	0.6	10
96	Translational research in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2014, 50, 345-352.	0.8	9
97	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Hong Kong Chinese. <i>International Journal of Cancer</i> , 2018, 143, 2289-2298.	2.3	9
98	Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. <i>Frontiers in Oncology</i> , 2019, 9, 253.	1.3	9
99	Radiotherapy in the management of glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3558-3567.	0.9	9
100	Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. <i>Nutrition Journal</i> , 2021, 20, 14.	1.5	9
101	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. <i>Cancer Management and Research</i> , 2022, Volume 14, 339-366.	0.9	9
102	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. <i>Cancers</i> , 2022, 14, 2587.	1.7	9
103	Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. <i>Scientific Reports</i> , 2018, 8, 7052.	1.6	8
104	Solar Ultraviolet Radiation and Vitamin D Deficiency on Epstein-Barr Virus Reactivation: Observational and Genetic Evidence From a Nasopharyngeal Carcinoma-Endemic Population. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa426.	0.4	7
105	Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 2122.	1.7	7
106	Perceived unmet supportive care needs and determinants of quality of life among head and neck cancer survivors: a research protocol. <i>Journal of Advanced Nursing</i> , 2013, 69, 2750-2758.	1.5	6
107	Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 446-455.	0.9	6
108	Limitation of radiological T3 subclassification of rectal cancer due to paucity of mesorectal fat in Chinese patients. <i>Hong Kong Medical Journal</i> , 2014, 20, 366-70.	0.1	6

#	ARTICLE	IF	CITATIONS
109	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1227-1236.	0.4	5
110	Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma. <i>Medical Dosimetry</i> , 2022, 47, 14-19.	0.4	5
111	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6022-6022.	0.8	5
112	Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. <i>Hong Kong Medical Journal</i> , 2017, 23, 54-62.	0.1	5
113	Management of Nasopharyngeal Carcinoma in Elderly Patients. <i>Frontiers in Oncology</i> , 2022, 12, 810690.	1.3	5
114	Contemporary management of the neck in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 1949-1963.	0.9	4
115	External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. <i>Cancers</i> , 2021, 13, 4286.	1.7	4
116	The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. <i>Chinese Clinical Oncology</i> , 2016, 5, 27-27.	0.4	4
117	A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis. <i>Radiotherapy and Oncology</i> , 2022, 168, 121-129.	0.3	4
118	Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 83-92.	0.9	4
119	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2679-2689.	3.2	4
120	Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. <i>Journal of Medical Economics</i> , 2017, 20, 541-548.	1.0	3
121	Special section on intensity-modulated radiation therapy for head and neck cancer (IMRT). <i>Oral Oncology</i> , 2019, 88, 49-50.	0.8	3
122	Treatment Outcomes of Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Series of 22 Patients and Treatment Strategy Review. <i>Hong Kong Journal of Radiology</i> , 2013, 16, 270-277.	0.1	3
123	International Consensus on Delineation of Target Volumes and Organs at Risk. , 2019, , 239-261.		2
124	Advances in Radiotherapy. , 2019, , 263-288.		2
125	Proton/heavy ion therapy in salvage of locally recurrent nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 2020, 4, 4-4.	0.5	2
126	Standardization for oncologic head and neck surgery. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4663-4669.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China. <i>Frontiers in Oncology</i> , 2021, 11, 699241.	1.3	2
128	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—“Magic Bullet or Pandora’s Box?”. <i>JAMA Oncology</i> , 2022, , .	3.4	2
129	The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 114-116.	0.4	2
130	Salvage of Local Recurrence. , 2019, , 289-312.		1
131	Knowledge-based planning in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 4, 6-6.	0.5	1
132	Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence from a multicenter case-control study. <i>Clinical Nutrition</i> , 2021, 40, 5180-5188.	2.3	1
133	Abstract 4773: Aberrant methylation at chromosome 6p as novel biomarkers for diagnosis and prognosis of nasopharyngeal carcinoma. , 2015, , .		1
134	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6029-6029.	0.8	1
135	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: <i>Quo Vadis?</i> . <i>Journal of Clinical Oncology</i> , 2022, 40, 1135-1138.	0.8	1
136	Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We Optimize Care?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 501-510.	1.8	1
137	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. <i>Frontiers in Oncology</i> , 2022, 12, 842281.	1.3	1
138	Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7-year audit. <i>Surgical Practice</i> , 2010, 14, 85-91.	0.1	0
139	Re-irradiation for recurrent NPC—is the treatment merited at all?. <i>Annals of Nasopharynx Cancer</i> , 0, 1, 1-1.	0.5	0
140	913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG. <i>Annals of Oncology</i> , 2020, 31, S659-S660.	0.6	0
141	Diagnosis and Staging of Nasopharyngeal Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 1-21.	0.0	0
142	Precision radiotherapy in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 5, 1-1.	0.5	0
143	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e217.	5.1	0
144	Nasopharynx. <i>Medical Radiology</i> , 2009, , 57-73.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Abstract 4148: Adverse effects of TERT-CLPTM1L and double-strand breaks repair contribute to risk for nasopharyngeal carcinoma. , 2014, , .		0
146	Five-year Treatment Outcomes for Stage II to III Rectal Cancer in a Single Cancer Institution. Hong Kong Journal of Radiology, 2014, 17, 255-266.	0.1	0
147	Abstract 1734: Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer. , 2015, , .		0
148	Management of Nasopharyngeal Carcinoma. , 2016, , 445-473.		0
149	Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 86-92.	0.8	0
150	In Reply to Abbasi et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263.	0.4	0
151	Induction Chemotherapy Docetaxel, Cisplatin, 5-Fluorouracil Followed by Concurrent Chemoradiotherapy in Stage IVA Nasopharyngeal Carcinoma. Clinical Oncology and Research, 2020, , 1-8.	0.1	0